Discussion page for Arch Therapeutics (ARTH)This page is for discussion of Arch Therapeutics (ARTH).
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Anybody see presentation yesterday. Anything new?
A ton of new stuff. Don’t miss it. https://www.veracast.com/webcasts/bio/ceoinvestor2019/33121486228.cfm?db=0.7073717013304248
excellent and encouraging presentation. Thanks
Interesting, they seem to be primarily focusing on the commercialization of the tropical wound product for the rest of this year. TN did not mention anything about partnering in this area. That is a little concerning as to commercialize requires money. And although he mentioned the IDE in 2019, no mention of what quarter, which in my Project Manager mind means Dec of this year. But at least progress was made in 2018, let’s hope it continues.
Duh – topical not tropical, I guess I have Kauai on my mind.
I am beginning to lose all confidence in Norchi, and it looks like the market feels the same way!!
What did you hear in the BIO presentation that made you begin to lose confidence in Norchi?
$ARTH way-too-Long
Did anybody else hear sincere enthusiasm and confidence in Norchi’s voice? as far as i’m concerned, that was probably the best presentations Norchi’s given in long time. Almost sounded like he was relieved.
Might be the accelerated/narrow time frame too, but he could squeeze all the important points, including advancing in biosurgical program. i’m also quite impressed about the fact that they’ve (finally) implemented broader spectrum of AC5 topical indications in to their strategy – Dermal Sciences is a good start AND sounded very deeply thought of. Next stops are eye diseases and inflammations, right?
I’d say good work during 2018. Now get us the distributor/partner and off we go with uplisting too.
$ARTH – Arch Therapeutics to Provide Corporate Update at the 31st Annual ROTH Conference
https://ir.archtherapeutics.com/press-releases/detail/523
ARTH long